People
Henry Li, Sorrento’s co-founder, director, president and chief executive officer, did a follow-up interview with BioSpace to discuss the news and speculation surrounding it.
The hopes of billions of people are riding on at least one of the vaccine candidates for COVID-19 currently in clinical development becoming a commercialized preventative treatment for the world. While hopes are high, caution is still being urged by drugmakers and epidemiologists.
Diabetes and obesity remain a problem, even during a pandemic. Eli Lilly is continuing to develop the 13 diabetes drugs it has in Phase I through Phase III trials, with data from various trials planned for release throughout the coming year.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 20, 2020.
The company reported overall positive results for both efficacy and safety, although not a lot of details were released on the actual data.
With its proprietary, top-down view of the immune system and purportedly the world’s largest proprietary data devoted to clinical immunologics, it aims to catalyze significant improvements in disease detection, diagnosis and treatment.
Expected to launch in June or July, the study plans to test as many as 325,000 people to learn how the SARS-CoV-2 virus is spreading nationally, according to Reuters, reporting before the official announcement.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 19, 2020.
U.S. demand for telehealth will soar by 64.3% in 2020 because of the COVID-19 pandemic, according to a report released by Frost & Sullivan.
Petros will be helmed by Charles S. Ryan, who currently serves as chief executive officer of Neurotrope.
PRESS RELEASES